Biocartis Company

Biocartis is a Swiss molecular diagnostics company that specializes in developing a diagnostics technology platform for the detection of bio-analytes. Their focus is on integrated molecular and immunodiagnostics using their proprietary micro-technology platform. Biocartis develops and licenses technologies for the detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Their products are used for various applications in the analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis was founded in 2007 and is committed to revolutionizing molecular testing with its unique proprietary IdyllaTM platform. Their focus is on oncology, providing next-generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers, and the healthcare industry.

Invests into

Investors

Connections

Founded Date: 2007-01-01 00:00:00
Last Funding Type: Grant
Headquarters: Lausanne, Vaud, Switzerland
Investors Number: 19
Technology: Longevity
Employee Number: 1-10
Industry: Elderly and Healthcare
Estimated Revenue: EUR 116 million
Last Funding Date: 2020-09-30 00:00:00
Funding Status: IPO
Total Funding: 418090872
Register and Claim Ownership